| Drug General Information |
| Drug ID |
D07IGC
|
| Former ID |
DNCL001933
|
| Drug Name |
DSP-8658
|
| Indication |
Alzheimer disease; Type 2 diabetes [ICD9: 331, 250; ICD10:G30, E11]
|
Phase 1 |
[1]
|
|---|
| Company |
Sunovion Pharmaceuticals
|
| Target and Pathway |
| Target(s) |
Peroxisome proliferator activated receptor gamma |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
AMPK signaling pathway
|
|
Osteoclast differentiation
|
|
Huntington's disease
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Thyroid cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
PANTHER Pathway
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Noncanonical Wnt signaling pathway
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Signaling events mediated by HDAC Class I
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
PPARA activates gene expression
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
Wnt Signaling Pathway Netpath
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Differentiation of white and brown adipocyte
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Adipogenesis
|
|
SREBP signalling
|
|
Nuclear Receptors
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01042106) Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults. U.S. National Institutes of Health. |
|---|
| REF 2 | Effects of DSP-8658, a Novel Selective Peroxisome Proliferator-activated Receptors a/gamma Modulator, on Adipogenesis and Glucose Metabolism in Diabetic Obese Mice. Exp Clin Endocrinol Diabetes. 2015Sep;123(8):492-9. |
|---|
